A growth in the systemic lupus erythematosus (SLE) and lupus nephritis (LN) market across the 7MM is anticipated, as per GlobalData.

Respondents from a GlobalData survey have identified drug pricing and reimbursement hurdles as one of the top three pharma ...

With big pharma signalling interest in novel RNA-targeted approaches, the term “druggable” is being redefined as technology advances.

Teijin Pharma has signed a joint research agreement with Aska Pharmaceutical to develop small-molecule drug candidates for ...

ExCellThera, along with its wholly owned subsidiary Cordex Biologics, has received Status 1 listing from the NUB programme in ...

The UK was the highest ranked country for those offshoring pharma R&D, raising questions about its pharma industry’s attractiveness.

As theranostic radiopharmaceuticals gain prevalence, companies must overcome associated regulatory, manufacturing and ...

The FDA's verdict on PTC's Translarna could spell the end for the drug's decades-long and tumultuous US DMD development ...

Disc Medicine has received a CRL from the US FDA concerning its New Drug Application (NDA) for bitopertin for EPP.

Lilly’s amassing of a $1.5bn pre-launch inventory follows sizeable investments into US manufacturing facilities.

Immunic has announced an oversubscribed private placement of up to $400m, strengthening its move from an R&D-focused organisation into a commercial-stage entity.

As drug potency increases, OEB 6 containment is becoming increasingly crucial for safe HPAPI manufacturing, driven by oncology growth, and complex payloads.